Valneva (NASDAQ:VALN - Get Free Report) had its target price cut by analysts at HC Wainwright from $23.00 to $20.00 in a research note issued on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 253.98% from the company's current price.
Valneva Price Performance
VALN stock traded down $0.04 during midday trading on Friday, reaching $5.65. The company had a trading volume of 19,613 shares, compared to its average volume of 10,891. The firm has a 50-day moving average price of $6.80 and a 200-day moving average price of $7.46. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.63 and a quick ratio of 2.15. The company has a market capitalization of $393.45 million, a P/E ratio of -13.88 and a beta of 2.17. Valneva has a 1 year low of $5.57 and a 1 year high of $14.49.
Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. On average, research analysts anticipate that Valneva will post 0.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Valneva
An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. boosted its stake in shares of Valneva SE (NASDAQ:VALN - Free Report) by 2.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 354,361 shares of the company's stock after acquiring an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
